The Present Study Sample Clauses

The Present Study. We conducted an experiment investigating the relationship between chronotype and facial affect processing in order to determine whether eveningness is related to social cognition. The review of individual chronotype differences reveals the possibility that eveningness may be a premorbid trait for depression. There are two reasons for this notion. First, a tendency towards eveningness may lead to SCN dysfunction, which in turn, may lead to mood disorders. Second, eveningness is associated with the presence of both mood disorders and factors related to mood disorders—such as abnormalities in physiology and sleep, similar light exposure, negative personality traits, and evening social interactions. These two reviews together reveal the manner in which eveningness may be related to social cognition. People who exhibit sleep deprivation, depression, and functioning at non- preferred times of day all show similar deficits in facial affect processing—namely, blunted perception of emotional intensity at lower levels of expressiveness, and decreased emotion recognition accuracy. Since evening types often experience sleep deprivation, social interaction at non-preferred times of day (such as during morning hours), and depression, it is possible that they might display these same facial affect processing deficits. If such a relationship is found, it would reveal social cognition to be another avenue through which eveningness and depression are related. More importantly, it would indicate that, in addition to depression, eveningness may also be a risk factor for social ineptitude. It is possible, however, for the converse to be true: pre- existing social ineptness may in fact be the cause of one’s eveningness and depression. Although the facial affect processing studies mentioned above detected both directional causality and the existence of processing deficits, the present study does not, as it follows a simple cross-sectional descriptive design. Rather, we simply set out to investigate if there was a difference between chronotypes in their ratings of emotional intensity. Findings from the previously mentioned studies enabled us to make two predictions:
AutoNDA by SimpleDocs
The Present Study. The seminal article describing the TGP details each of the structures of the theory and states that they are intertwined [34], but specific operational mechanisms were not explored. Moreover, the potential of any of the domains or constructs to serve as a central mediator was not articulated [32]. Although there has been no formal test of the model in its entirety, many of the model constructs have been explored as correlates of condom use in other contexts. Thus, the existing literature provides data for a two- pronged research approach: 1) to systematically explore associations of TGP constructs with condom use among African American young women, and 2) to systematically explore associations between TGP constructs to better explicate how the three structures of the theory are connected.
The Present Study. A great advantage to designing interventions based on frameworks such as the TGP is that the theoretical constructs provide psychological and behavioral targets to improve the likelihood of behavioral change. Interventions aimed at changing behaviors (e.g. condom use) often do so by enhancing theoretical mediators of the behavior (e. g. condom use negotiation) [113]. It is also of value to explore these mediators not only as intervention targets but as potential links in multiple chains that begin with other theoretical constructs in order to explicate how those factors fit into a larger mechanism that predicts condom use. Additionally, analysis of theoretical constructs that may be antecedents to important mediators of behavioral change can illuminate whether background variables indicate important areas of diversity in the target population and can aid in the refinement of intervention strategies [114]. Developing statistical models in the social sciences can lead to conclusions that are dependent upon validation in other samples. Indeed, “models are best regarded as approximations to reality rather than as exact statements of truth” [186]. A practice that allows researchers to develop a model through exploratory methods in one sample and test the best fitting model as a legitimate hypothesis in another is that of cross validation [187]. When two samples are not available, a single sample may be randomly split into a calibration and validation sample. In structural equation modeling, hypotheses regarding measurement of constructs and associations between constructs can be confirmed in this manner. This study empirically tested how acquired economic, social and physical risks and personal and behavioral risk factors directly and indirectly predicted condom use among African American young women. No studies have tested communication as a central mediator of acquired risks of all three domains of the TGP. Furthermore, conservative religious beliefs have not been previously measured in a manner consistent with the TGP among a sample of African American young women. The study goals were to randomly split a sample of African American young women into calibration and validation samples and (1) test a measurement model of observed variables and latent constructs described by the TGP, (2) test a structural equation model of the latent variables and (3) validate the model through multi-group analysis with equality constraints using structural equation modeling.

Related to The Present Study

  • Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Independent Study Independent study is a program of independent study, research, and/or experience directly related to the duties described in the employee’s job description or related classification as determined by the Retraining and Study Committee, which promises professional values equivalent to that derived from formal study at a recognized educational institution.

  • The Study 2.1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Trials The Ship shall run the following test and trials:

  • Feasibility Study 4.3.1 The Feasibility Study shall identify any potential adverse system impacts that would result from the interconnection of the Generating Facility.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.